Skip to content
10-Q

Quarterly Report

ACCENTIA BIOPHARMACEUTICALS INC

0001193125-12-052836

← back to feed
Filed
Feb 10, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2012 · Jan 31, 2012 76.04M sh
Capex Q1 2012 · Dec 31, 2011 $97.5K
Capex Q1 2012 · Dec 31, 2010 $98.4K
Operating Cash Flow Q1 2012 · Dec 31, 2011 −$1.35M
Operating Cash Flow Q1 2012 · Dec 31, 2010 −$1.3M
Cash And Equivalents Q1 2012 · Dec 31, 2011 $297.03K
Cash And Equivalents Q1 2012 · Sep 30, 2011 $420.54K
Cash And Equivalents Q1 2012 · Dec 31, 2010 $3.76M
Cash And Equivalents Q1 2012 · Sep 30, 2010 $558.45K
Stockholders Equity Q1 2012 · Dec 31, 2011 −$71.33M
Stockholders Equity Q1 2012 · Sep 30, 2011 −$74.56M
Current Liabilities Q1 2012 · Dec 31, 2011 $60.55M
Current Liabilities Q1 2012 · Sep 30, 2011 $31.27M
Total Liabilities Q1 2012 · Dec 31, 2011 $90.05M
Total Liabilities Q1 2012 · Sep 30, 2011 $92.97M
Current Assets Q1 2012 · Dec 31, 2011 $4.09M
Current Assets Q1 2012 · Sep 30, 2011 $2.87M
Total Assets Q1 2012 · Dec 31, 2011 $5.64M
Total Assets Q1 2012 · Sep 30, 2011 $5.91M
Eps Diluted Q1 2012 · Dec 31, 2011 $0.01
Eps Diluted Q1 2012 · Dec 31, 2010 −$0.08
Sga Expense Q1 2012 · Dec 31, 2011 $1M
Sga Expense Q1 2012 · Dec 31, 2010 $12.2M
Rd Expense Q1 2012 · Dec 31, 2011 $961.67K
Rd Expense Q1 2012 · Dec 31, 2010 $293.8K
Operating Income Q1 2012 · Dec 31, 2011 −$1.4M
Operating Income Q1 2012 · Dec 31, 2010 −$12.16M
Gross Profit Q1 2012 · Dec 31, 2011 $593.16K
Gross Profit Q1 2012 · Dec 31, 2010 $358.02K
Cost Of Revenue Q1 2012 · Dec 31, 2011 $639.58K
Cost Of Revenue Q1 2012 · Dec 31, 2010 $553.97K
Revenue Q1 2012 · Dec 31, 2011 $1.23M
Revenue Q1 2012 · Dec 31, 2010 $911.99K